Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PRS036
MIFTS: 53

Parasitic Protozoa Infectious Disease

Categories: Cancer diseases, Infectious diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Parasitic Protozoa Infectious Disease

About this section

MalaCards integrated aliases for Parasitic Protozoa Infectious Disease:

Name: Parasitic Protozoa Infectious Disease 12 15
Protozoan Infections 45 74
Sarcomastigophora Infectious Disease 12
Mastigophora Infectious Disease 12

Classifications:

MalaCards categories:
Global: Infectious diseases Cancer diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:2789
MeSH 45 D011528
NCIt 51 C34953
SNOMED-CT 69 89933001 95896000
ICD10 34 B50-B64 B64
UMLS 74 C0033740
Sources

Summaries for Parasitic Protozoa Infectious Disease

About this section
Disease Ontology : 12 A parasitic infectious disease that is caused by parasitic protozoa which are microorganisms classified as unicellular eukaryotes.

MalaCards based summary : Parasitic Protozoa Infectious Disease, also known as protozoan infections, is related to trypanosomiasis and leishmaniasis. An important gene associated with Parasitic Protozoa Infectious Disease is MT-CYB (Mitochondrially Encoded Cytochrome B), and among its related pathways/superpathways are Allograft rejection and Immune response NFAT in immune response. The drugs Primaquine and Mefloquine have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and heart, and related phenotypes are hematopoietic system and homeostasis/metabolism

Sources

Related Diseases for Parasitic Protozoa Infectious Disease

About this section

Diseases related to Parasitic Protozoa Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 202)
# Related Disease Score Top Affiliating Genes
1 trypanosomiasis 32.4 ICAM1 IFNG IL10 IL2 IL4 TNF
2 leishmaniasis 32.3 HSPA4 IFNG IL10 IL4 LMLN TNF
3 coccidiosis 32.3 HSPA4 IFNG IL10 IL2 IL4 MT-CYB
4 malaria 31.7 ACKR1 G6PD HSPA4 ICAM1 IFNG IL10
5 gastroenteritis 30.6 IL10 IL4 TNF
6 toxoplasmosis 30.5 IFNG IL10 IL4 TNF
7 echinococcosis 30.5 IFNG IL10 MT-CO1 TNF
8 filariasis 30.5 IFNG IL10 IL2 TNF
9 cryptosporidiosis 11.4
10 primary amebic meningoencephalitis 11.3
11 granulomatous amebic encephalitis 11.3
12 giardiasis 11.3
13 balantidiasis 11.3
14 trichomoniasis 11.3
15 theileriasis 11.3
16 amebiasis 11.3
17 dientamoebiasis 11.3
18 babesiosis 11.3
19 protozoal dysentery 11.0
20 sporotrichosis 10.6 IFNG IL10
21 lice infestation 10.6 KDR MT-CO1
22 punctate inner choroidopathy 10.6 IL10 TNF
23 bacterial infectious disease 10.6 IFNG IL10 TNF
24 oral tuberculosis 10.6 IL2 TNF
25 tropical endomyocardial fibrosis 10.6 IL10 IL4 TNF
26 endomyocardial fibrosis 10.6 IL10 IL4 TNF
27 tungiasis 10.6 IL10 IL4 TNF
28 hyperlucent lung 10.5 IFNG IL10 IL4
29 nickel allergic contact dermatitis 10.5 IFNG IL10 IL4
30 chronic graft versus host disease 10.5 IFNG IL10 TNF
31 baylisascariasis 10.5 IFNG IL10 IL4
32 scleritis 10.5 IFNG IL4 TNF
33 hemorrhagic fever 10.5 IFNG IL10 TNF
34 spotted fever 10.5 IFNG IL10 TNF
35 aseptic meningitis 10.5 IFNG IL10 TNF
36 meningitis 10.5 IFNG IL10 TNF
37 buruli ulcer 10.5 IFNG IL10 IL4
38 genital herpes 10.5 ACKR1 IL10 IL4
39 cephalosporin allergy 10.5 IFNG IL10
40 scrub typhus 10.5 IL10 TCN2 TNF
41 keratoconjunctivitis sicca 10.5 IL10 IL4 TNF
42 gaucher disease, type ii 10.5 IL10 IL2 IL4
43 paranasal sinus disease 10.5 IFNG IL10 IL4
44 chronic active epstein-barr virus infection 10.5 IFNG IL10 IL2
45 rheumatic heart disease 10.5 IL10 IL4 TNF
46 crohn's colitis 10.5 IFNG IL2 TNF
47 commensal bacterial infectious disease 10.5 IL10 IL2 TNF
48 bardet-biedl syndrome 15 10.5 ICAM1 IL10 IL4
49 atopic keratoconjunctivitis 10.5 IFNG IL2 IL4
50 mixed connective tissue disease 10.5 IFNG IL10 TNF

Graphical network of the top 20 diseases related to Parasitic Protozoa Infectious Disease:



Diseases related to Parasitic Protozoa Infectious Disease
Sources

Symptoms & Phenotypes for Parasitic Protozoa Infectious Disease

About this section

MGI Mouse Phenotypes related to Parasitic Protozoa Infectious Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.85 G6PD ICAM1 IFNG IL10 IL2 IL4
2 homeostasis/metabolism MP:0005376 9.73 ACKR1 G6PD ICAM1 IFNG IL10 IL2
3 immune system MP:0005387 9.36 ACKR1 ICAM1 IFNG IL10 IL2 IL4
Sources

Drugs & Therapeutics for Parasitic Protozoa Infectious Disease

About this section

Drugs for Parasitic Protozoa Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 441)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Primaquine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 90-34-6 4908
2
Mefloquine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 53230-10-7 4046
3
Artesunate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 88495-63-0 5464098 6917864
4
Permethrin Approved, Investigational Phase 4,Phase 3,Not Applicable 52645-53-1 40326
5
chloroquine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54-05-7 2719
6
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83905-01-5 55185 447043
7
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
8
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-14-0 4993
9
Sulfadoxine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2447-57-6 17134
10
Artemether Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 71963-77-4 119380 68911
11
Lumefantrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 82186-77-4 6437380
12
Quinine Approved Phase 4,Phase 3,Phase 2,Not Applicable 130-95-0 8549 3034034
13
Amodiaquine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 86-42-0 2165
14
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Not Applicable 103-90-2 1983
15
Albendazole Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 54965-21-8 2082
16
Praziquantel Approved, Investigational, Vet_approved Phase 4,Not Applicable 55268-74-1 4891
17
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
18
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1397-89-3 14956 5280965
19
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
20
Iron Approved, Experimental Phase 4,Phase 3,Not Applicable,Early Phase 1 7439-89-6, 15438-31-0 23925 27284
21
Proguanil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 500-92-5 4923
22
Atovaquone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 95233-18-4 74989
23
Miltefosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58066-85-6 3600
24
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 738-70-5 5578
25
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 2,Not Applicable 723-46-6 5329
26
Morphine Approved, Investigational Phase 4 57-27-2 5288826
27
Nevirapine Approved Phase 4,Phase 3,Early Phase 1 129618-40-2 4463
28
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 1 94-09-7, 1994-09-7 2337
29
tannic acid Approved Phase 4,Phase 2,Phase 1 1401-55-4
30
Dapsone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 80-08-0 2955
31
Ibuprofen Approved Phase 4,Phase 2,Not Applicable 15687-27-1 3672
32
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
33
Copper Approved, Investigational Phase 4,Phase 3,Not Applicable 7440-50-8 27099
34
Nicotinamide Approved, Investigational Phase 4,Phase 3,Not Applicable 98-92-0 936
35
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7553-56-2 807
36
Tocopherol Approved, Investigational Phase 4,Phase 3,Not Applicable 1406-66-2 14986
37
Methylcobalamin Approved, Experimental, Investigational Phase 4,Phase 3,Not Applicable 13422-55-4
38
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7440-66-6 32051
39
Selenium Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 7782-49-2
40
Hydroxocobalamin Approved Phase 4,Phase 3,Not Applicable 13422-51-0 11953898 15589840
41
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3 137-58-6 3676
42
deoxycholic acid Approved Phase 4,Phase 3,Not Applicable 83-44-3 222528
43
Paromomycin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1263-89-4, 7542-37-2 165580
44
Metronidazole Approved Phase 4,Phase 3,Phase 2,Not Applicable 443-48-1 4173
45
Piperazine Approved, Vet_approved Phase 4 110-85-0 4837
46
Sodium Citrate Approved, Investigational Phase 4,Not Applicable 68-04-2
47
Mebendazole Approved, Vet_approved Phase 4,Not Applicable 31431-39-7 4030
48
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
49
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
50
Enalaprilat Approved Phase 4 76420-72-9 6917719

Interventional clinical trials:

(show top 50) (show all 1262)
# Name Status NCT ID Phase Drugs
1 Malaria Elimination Pilot Study in Military Forces in Cambodia Unknown status NCT02653898 Phase 4 DHA-PIP;Primaquine;Artesunate + Mefloquine;Permethrin (Insecticide treated uniform)
2 Evaluating the Efficacy of Chloroquine for the Treatment of Plasmodium Vivax Infections in Central Vietnam Unknown status NCT02610686 Phase 4 Chloroquine
3 P. Falciparum Resistance to Artemisinin in Vietnam Unknown status NCT02604966 Phase 4 Artesunate (AS) group;DHA - PPQ group
4 A Safety, Tolerability, Pharmacokinetic and Efficacy Study of Azithromycin Plus Piperaquine as Presumptive Treatment in Pregnant PNG Women Unknown status NCT02575755 Phase 4 Azithromycin plus piperaquine phosphate;Sulfadoxine-pyrimethamine
5 Targeted Indoor Residual Spraying Against Malaria Unknown status NCT02556242 Phase 4
6 Investigation of Short Course, High Dose Primaquine Treatment for Liver Stages of Plasmodium Vivax Infection Unknown status NCT02364583 Phase 4 Primaquine
7 The Optimal Timing Of Primaquine To Prevent Malaria Transmission After Artemisinin-Combination Therapy Unknown status NCT01906788 Phase 4 Artemether Lumefantrine;Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0;Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2
8 Intravenous Artesunate and Malaria Unknown status NCT01805232 Phase 4 artesunate;Quinine
9 Impact of Insecticide Resistance on Vector Control Unknown status NCT01713517 Phase 4
10 Improving Anti-malarial Treatment Options in Guinea-Bissau - Part A Unknown status NCT01704508 Phase 4 Artemether-lumefantrine;Dihydroartemisinin-piperaquine
11 The Combined Use of Indoor Residual Spraying (IRS) and Long-lasting Insecticidal Nets (LLINs) for Malaria Prevention Unknown status NCT01697852 Phase 4
12 Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand Unknown status NCT01662700 Phase 4 Artesunate;Chloroquine
13 Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan Unknown status NCT01075945 Phase 4 Dihydroartemisinin- piperaquine;artemether- lumefantrine
14 Safety and Effectiveness of Artemisinin-based Combination Therapies (ACTs) With Repeated Treatments for Uncomplicated Falciparum Malaria Over a Three-year Period Unknown status NCT01038063 Phase 4 Artemether-lumefantrine combination
15 Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria Unknown status NCT00902811 Phase 4 AM(FDC);AM(LT);AL;DP;AA(FDC)
16 Evaluation of the Public Health Impact of Seasonal Intermittent Preventive Treatment (IPT) in Children in Senegal Unknown status NCT00712374 Phase 4 sulfadoxine-pyrimethamine plus amodiaquine
17 Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children Unknown status NCT00540202 Phase 4 artemether-lumefantrine;Oral quinine
18 Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate Unknown status NCT00238017 Phase 4 amodiaquine-artesunate versus amodiaquine
19 Intermittent Antimalaria Treatment With SP in African Children Unknown status NCT00168948 Phase 4 Sulfadoxin (12.5) Pyrimethamine (250 mg)
20 The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau Unknown status NCT00137566 Phase 4 acetaminophen (paracetamol)
21 Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana Unknown status NCT01459146 Phase 4 Artemether-lumefantrine combination plus albendazole;Artemether-lumefantrine plus Praziquantel plus Albendazole;Albendazole plus Praziquantel
22 Assessment of Artesunate/Mefloquine in the Peruvian Amazon Unknown status NCT02084602 Phase 4 Artesunate;Mefloquine
23 Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics Unknown status NCT01944189 Phase 4
24 Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis Unknown status NCT01566552 Phase 4 AMBISOME
25 Clinical Assessment, Neuroimaging and Immunomarkers in Chagas Disease Study (CLINICS) Unknown status NCT01650792 Phase 4 Aspirin
26 Efficacy and Safety of Artesunate + Amodiaquine With SLD of Primaquine for Treatment of Falciparum Malaria in Zanzibar Completed NCT03773536 Phase 4 Artesunate-amodiaquine given with single low dose primaquine
27 Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine for Falciparum Malaria in Zanzibar, 2005 Completed NCT03768908 Phase 4 Artemether-lumefantrine;Artesunate + Amodiaquine
28 Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar Completed NCT03764527 Phase 4 Artemether-lumefantrine;Coadministered Artesunate plus Amodiaquine
29 Efficacy and Safety of ASAQ and PD for the Treatment of Uncomplicated Falciparum Malaria in Mainland Tanzania Completed NCT03431714 Phase 4 Artesunate amodiaquine
30 Efficacy and Safety of Artemisinin-based Combination Treatments in the Democratic Republic of the Congo Completed NCT02940756 Phase 4 artesunate-amodiaquine;artemether-lumefantrine;Dihydroartemisinine-piperaquine
31 Prevention of Malaria With Dihydroartemisinine + Piperaquine for Forest Rangers Completed NCT02788864 Phase 4 Arterakine (DHA/piperaquine);Placebo
32 Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo Completed NCT02741024 Phase 4 Amodiaquine-Artesunate (ASAQ);Artemether-Lumefantrine (AL)
33 In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria Completed NCT02637128 Phase 4 artemether-lumefantrine (AL);artesunate-amodiaquine (ASAQ)
34 A Study to Assess Current Standard Malaria Treatment Guidelines in the Republic of the Sudan Completed NCT02592408 Phase 4 ASP;SDPQ;14DPQ;14DPQ on Day 42
35 In-vivo Efficacy and Safety of Artemether/Lumefantrine Vs Dihydroartemisinin-piperaquine for Treatment of Uncomplicated Malaria and Assessment of Parasite Genetic Factors Associated With Parasite Clearance or Treatment Failure Completed NCT02590627 Phase 4 Artemether-lumefantrine;Dihydroartemisinin-piperaquine
36 Accelerating the Reduction of Malaria Transmission in Kanel, Ranérou and Linguère Districts Completed NCT02536222 Phase 4
37 Effectiveness of Malaria Treatment in Mexico Completed NCT02394197 Phase 4 Chloroquine phosphate;primaquine
38 A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh Completed NCT02389374 Phase 4 chloroquine;Artemether-lumefantrine combination;Primaquine;Primaquine
39 Artemisinin-based Combination Therapy for Treatment of Plasmodium Falciparum Malaria in North Sumatera, Indonesia Completed NCT02325180 Phase 4 Dihydroartemisinin-Piperaquine;Artemether-lumefantrine
40 In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children Completed NCT02168569 Phase 4 Coartemâ„¢ (Artemether-lumefantrine combination);Coarsucamâ„¢ (Amodiaquine-artesunate combination)
41 Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity Completed NCT02143934 Phase 4 Primaquine;Placebo;Chloroquine;Artemether Lumefantrine
42 Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia: Completed NCT02118090 Phase 4 Chloroquine sulfate;DHA-PP
43 Efficacy and Safety of a Single Low-dose Primaquine for the Clearance of Gametocytes Completed NCT02090036 Phase 4 Primaquine (For artemether-lumefantrine+primaquine arm);Placebo (For artemether-lumefantrine arm)
44 Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria. Completed NCT02089841 Phase 4 Artemether-lumefantrine
45 Harmonized AS/MQ Efficacy Study - Thailand Completed NCT02052323 Phase 4 Artesunate/mefloquine (AS/MQ)
46 School-Based Treatment With ACT to Reduce Transmission Completed NCT02009215 Phase 4 Dihydroartemisinin-piperaquine (DP)
47 In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy Completed NCT01976780 Phase 4 Artesunate;Artemether Lumefantrine;Mefloquine
48 Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO Completed NCT01930331 Phase 4 artemisinin/naphthoquine;dihydroartemisinin/piperaquine phosphate
49 The Role of Rapid Diagnostic Tests for Malaria for Targeting of ACTs at Community Level Completed NCT01907672 Phase 4
50 Surveillance and Treatment With Dihydroartemisinin-piperaquine Plus Primaquine Completed NCT01878357 Phase 4 dihydroartemisinin-piperaquine;primaquine

Search NIH Clinical Center for Parasitic Protozoa Infectious Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: protozoan infections

Sources

Genetic Tests for Parasitic Protozoa Infectious Disease

About this section
Sources

Anatomical Context for Parasitic Protozoa Infectious Disease

About this section

MalaCards organs/tissues related to Parasitic Protozoa Infectious Disease:

42
Testes, Liver, Heart, Skin, Brain, Breast, T Cells
Sources

Publications for Parasitic Protozoa Infectious Disease

About this section

Articles related to Parasitic Protozoa Infectious Disease:

(show top 50) (show all 98)
# Title Authors Year
1
Island-Wide Surveillance of Gastrointestinal Protozoan Infections on Fiji by Expanding Lymphatic Filariasis Transmission Assessment Surveys as an Access Platform. ( 29405101 )
2018
2
Intestinal helminths and protozoan infections in patients with colorectal cancer: prevalence and possible association with cancer pathogenesis. ( 30220046 )
2018
3
Effects of Water, Sanitation, Handwashing, and Nutritional Interventions on Child Enteric Protozoan Infections in Rural Bangladesh: A Cluster-Randomized Controlled Trial. ( 29669039 )
2018
4
Human Kinetoplastid Protozoan Infections: Where Are We Going Next? ( 30090098 )
2018
5
Artemisinin and its derivatives in treating protozoan infections beyond malaria. ( 27867026 )
2017
6
Epidemiology of Soil-Transmitted Helminth and Intestinal Protozoan Infections in Preschool-Aged Children in the Amhara Region of Ethiopia. ( 28167597 )
2017
7
The Roles of Mast Cells in Parasitic Protozoan Infections. ( 28428784 )
2017
8
The Mini-FLOTAC technique for the diagnosis of helminth and protozoan infections in humans and animals. ( 28771238 )
2017
9
Molecular Biology Can Change the Classic Laboratory Approach for Intestinal Protozoan Infections. ( 29163458 )
2017
10
Prevalence and Risk Factors for Intestinal Protozoan Infections with Cryptosporidium, Giardia, Blastocystis and Dientamoeba among Schoolchildren in Tripoli, Lebanon. ( 26974335 )
2016
11
Correction: Prevalence and Risk Factors for Intestinal Protozoan Infections with Cryptosporidium, Giardia, Blastocystis and Dientamoeba among Schoolchildren in Tripoli, Lebanon. ( 27081847 )
2016
12
Trends in prevalence of soil-transmitted helminth and major intestinal protozoan infections among school-aged children in Nepal. ( 27097973 )
2016
13
Prevalence and risk factors of intestinal protozoan infections: a population-based study in rural areas of Boyer-Ahmad district, Southwestern Iran. ( 27884121 )
2016
14
PREVALENCE OF INTESTINAL PROTOZOAN INFECTIONS AMONG CHILDREN IN THAILAND: A LARGE-SCALE SCREENING AND COMPARATIVE STUDY OF THREE STANDARD DETECTION METHODS. ( 29634157 )
2016
15
Protozoan infections in farmed fish from Brazil: diagnosis and pathogenesis. ( 25909248 )
2015
16
Prevalence of intestinal protozoan infections among individuals living with HIV/AIDS at Felegehiwot Referral Hospital, Bahir Dar, Ethiopia. ( 25917962 )
2015
17
To bet or not to bet: deciphering cell to cell variation in protozoan infections. ( 26070403 )
2015
18
A cross-sectional analysis of clinical presentations of and risk factors for enteric protozoan Infections in an Active Duty Population during Operation Iraqi Freedom. ( 28883934 )
2015
19
Recurrent wheezing is associated with intestinal protozoan infections in Warao Amerindian children in Venezuela: a cross-sectional survey. ( 24885094 )
2014
20
Marked antigiardial activity of Yucca baccata extracts: a potential natural alternative for treating protozoan infections. ( 25250335 )
2014
21
Epidemiology and geographical distribution of enteric protozoan infections in sydney, australia. ( 25343139 )
2014
22
The Regulation of CD4(+) T Cell Responses during Protozoan Infections. ( 25352846 )
2014
23
Comparison between Quantitative Buffy Coat (QBC) and Giemsa-stained Thin Film (GTF) technique for blood protozoan infections in wild rats. ( 25382468 )
2014
24
Breast-feeding protects infantile diarrhea caused by intestinal protozoan infections. ( 24327776 )
2013
25
Diagnosis of multiple enteric protozoan infections by enzyme-linked immunosorbent assay in the Guatemalan highlands. ( 23185076 )
2013
26
Intestinal protozoan infections in the immunocompromised host. ( 23806893 )
2013
27
Prevalence of intestinal protozoan infections among Orang Asli schoolchildren in Pos Senderut, Pahang, Malaysia. ( 24640856 )
2013
28
The epidemiology of soil-transmitted helminth and protozoan infections in south-west Cameroon. ( 21281528 )
2012
29
Macrophage migration inhibitory factor in protozoan infections. ( 22496958 )
2012
30
Giardia lamblia and respiratory allergies: a study of children from an urban area with a high incidence of protozoan infections. ( 22622669 )
2012
31
Protozoan infections of the gastrointestinal tract. ( 22632642 )
2012
32
Therapy of vector-borne protozoan infections in nonendemic settings. ( 21609269 )
2011
33
Current developments in the therapy of protozoan infections. ( 21629507 )
2011
34
Factors associated with high prevalence of intestinal protozoan infections among patients in Sana'a City, Yemen. ( 21789210 )
2011
35
Styrax japonica supplementation diet enhances the innate immune response in Epinephelus bruneus against bacterial and protozoan infections. ( 21824474 )
2011
36
Galectin-11 induction in the gastrointestinal tract of cattle following nematode and protozoan infections. ( 21958368 )
2011
37
Macrophage migration inhibitory factor (MIF): a key player in protozoan infections. ( 22110378 )
2011
38
Intestinal protozoan infections in relation to nutritional status and gastrointestinal morbidity in Colombian school children. ( 20061400 )
2010
39
Patterns of protozoan infections: spatiotemporal associations with cattle density. ( 20229128 )
2010
40
Validation of multiple diagnostic techniques to detect Cryptosporidium sp. and Giardia sp. in free-ranging western lowland gorillas (Gorilla gorilla gorilla) and observations on the prevalence of these protozoan infections in two populations in Gabon. ( 20597211 )
2010
41
Heat shock protein 90 as a drug target against protozoan infections: biochemical characterization of HSP90 from Plasmodium falciparum and Trypanosoma evansi and evaluation of its inhibitor as a candidate drug. ( 20837488 )
2010
42
Importance of nonenteric protozoan infections in immunocompromised people. ( 20930074 )
2010
43
A survey of intestinal protozoan infections among gastroenteritis patients during a 3-year period (2004-2006) in Gyeonggi-do (province), South Korea. ( 19724707 )
2009
44
Targeting caspases in intracellular protozoan infections. ( 18785049 )
2009
45
Treatment of intestinal protozoan infections in children. ( 19329448 )
2009
46
The incidence, intensity and host morbidity of human parasitic protozoan infections in gastrointestinal disorder outpatients in Buea Sub Division, Cameroon. ( 20130377 )
2009
47
Development of protease inhibitors for protozoan infections. ( 18978536 )
2008
48
Alternatively activated macrophages in protozoan infections. ( 17628461 )
2007
49
Epidemiology of parasitic protozoan infections in Soay sheep (Ovis aries L.) on St Kilda. ( 16978448 )
2007
50
Human waterborne trematode and protozoan infections. ( 17499101 )
2007
Sources

Variations for Parasitic Protozoa Infectious Disease

About this section
Sources

Expression for Parasitic Protozoa Infectious Disease

About this section
Search GEO for disease gene expression data for Parasitic Protozoa Infectious Disease.
Sources

Pathways for Parasitic Protozoa Infectious Disease

About this section

Pathways related to Parasitic Protozoa Infectious Disease according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Allograft rejection 1 38
Show member pathways
 12.83 HSPA4 ICAM1 IFNG IL10 IL2 IL4
2
Immune response NFAT in immune response 23
Show member pathways
 12.61 IFNG IL10 IL2 IL4 TNF
3
Th17 cell differentiation 38
Show member pathways
 12.57 IFNG IL10 IL2 IL4 TNF
4
Influenza A 38
Show member pathways
 12.55 ICAM1 IFNG IL2 IL4 TNF
5
NF-kappaB Signaling 4
12.54 IFNG IL10 IL2 IL4 TNF
6
Immune response Role of DAP12 receptors in NK cells 23
Show member pathways
 12.48 ICAM1 IFNG IL2 IL4 TNF
7
T cell receptor signaling pathway 38
Show member pathways
 12.39 IFNG IL10 IL2 IL4 TNF
8
JAK-STAT signaling pathway (KEGG) 66
Show member pathways
 12.35 IFNG IL10 IL2 IL4
9
Toxoplasmosis 38
Show member pathways
 12.23 IFNG IL10 IL4 TNF
10
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.21